US Edition#Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
#Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Pioneering Advances in Bradykinin-Mediated Angioedema: Pharvaris Unveils Promising Data on Deucrictibant In a significant stride towards addressing the unmet medical needs of patients with bradykinin-mediated disorders, Pharvaris, a late-stage biopharmaceutical company, has recently presented compelling data supporting the ongoing clinical development of its innovative oral bradykinin B2 receptor antagonist, Deucrictibant. The presentation took …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
